



## SPECIAL REPORT

**Evidence for 5-HT<sub>7</sub> receptors mediating relaxation of human colonic circular smooth muscle**

\*<sup>1,2</sup>Nicolaas H. Prins, <sup>1,3</sup>Michel R. Briejer, <sup>1</sup>Patrick J.E. Van Bergen, <sup>2</sup>Louis M.A. Akkermans & <sup>1</sup>Jan A.J. Schuurkes

<sup>1</sup>Department of Gastrointestinal Pharmacology, Janssen Research Foundation, Beerse, Belgium and <sup>2</sup>Gastrointestinal Motility Unit, Department of Surgery, Academic Medical Centre Utrecht, The Netherlands

5-HT<sub>4</sub> receptors mediate relaxation of human colon circular muscle. However, after 5-HT<sub>4</sub> receptor blockade (SB 204070 10 nM), 5-HT still induced a relaxation (pEC<sub>50</sub> 6.3). 5-HT<sub>4</sub> receptors were sufficiently blocked, as the curves to 5-HT obtained in the presence of 10 and 100 nM SB 204070 were indistinguishable. This 5-HT-induced relaxation was tetrodotoxin-insensitive, indicative of a smooth muscle relaxant 5-HT receptor. This, and the rank order of potency (5-CT = 5-MeOT = 5-HT) suggested involvement of 5-HT<sub>1</sub> or 5-HT<sub>7</sub> receptors. Mesulergine, a 5-HT<sub>7</sub> receptor antagonist at nanomolar concentrations, and a 5-HT<sub>1</sub> receptor antagonist at micromolar concentrations, competitively antagonized the 5-HT-induced relaxation (pK<sub>B</sub> 8.3) and antagonized the relaxation to 5-CT. Methysergide antagonized the 5-HT-induced relaxation (pA<sub>2</sub> 7.6). It is concluded that the profile of the smooth muscle inhibitory 5-HT receptor resembles that of the 5-HT<sub>7</sub> receptor. These data provide the first evidence for functional human 5-HT<sub>7</sub> receptors.

**Keywords:** 5-HT<sub>7</sub> receptors; 5-HT; human; colon; circular muscle

**Abbreviations:** CCh, carbachol; MES, mesulergine

**Introduction** In studies to investigate 5-HT-induced responses in circular colonic muscle strips, it was demonstrated that 5-HT<sub>4</sub> receptors mediate relaxation (Tam *et al.*, 1995; 5-HT<sub>4</sub> receptors mediating inhibition of spontaneous contractility; McLean & Coupar, 1995; 5-HT<sub>4</sub> receptors mediating direct relaxation). However, the 5-HT-induced relaxation could not be ascribed to a homogeneous 5-HT<sub>4</sub> receptor population. The selective 5-HT<sub>4</sub> receptor antagonist GR113808 shifted the response curve to 5-HT rightward at nanomolar concentrations, but at higher concentrations, GR113808 did not shift the curve to 5-HT further, which was reflected in a decrease in pA<sub>2</sub> estimates with increasing concentrations of antagonist (McLean *et al.*, 1995; Tam *et al.*, 1995). This suggests that the 5-HT-induced relaxation also involved a non-5-HT<sub>4</sub> receptor mechanism.

Interestingly, we found that in the presence of 5-HT<sub>4</sub> receptor blockade (induced by SB 204070), 5-HT was still able to relax the carbachol-contracted tissue and in the current study we describe the characterization of this non-5-HT<sub>4</sub> receptor-mediated relaxation of human colonic circular muscle.

**Methods** Segments of ascending, transverse, descending and sigmoid colon and rectum were obtained from patients that underwent surgery for colonic cancer (with the approval of the local Ethics Committee). The segment of colon was cut open longitudinally and luminal contents were rinsed out with modified Krebs-Henseleit solution (containing (mM): glucose 11.1, CaCl<sub>2</sub> 2.51, NaHCO<sub>3</sub> 25, MgSO<sub>4</sub> 1.18, KH<sub>2</sub>PO<sub>4</sub> 1.18, KCl 4.69 and NaCl 118) and the mucosa and mesentery were removed. The Krebs-Henseleit solution contained SB 204070

\*Author for correspondence at: Department of Gastrointestinal Pharmacology, Janssen Research Foundation, Turnhoutsebaan 30, 2340-B, Beerse, Belgium

<sup>3</sup>Current address: Yamanouchi Europe BV, Biological R&D, Leiderdorp, The Netherlands

(10 nM) throughout the experiments to block 5-HT<sub>4</sub> receptors, with the exception of one experiment, that was carried out in the presence of methysergide (1 μM), to demonstrate the 5-HT<sub>4</sub> receptor-mediated component of the relaxation. From the intertaenial region, circular muscle strips of approximately 2–3 cm length and 2–3 mm width were cut. The strips were anchored to organ bath hooks and suspended in a classical organ bath set-up for isotonic measurement (2 g load). The baths were filled with Krebs solution, gassed with carbogen (95% O<sub>2</sub>, 5% CO<sub>2</sub>) and kept at 37°C. After set-up, the strips were left to stabilize for a period of 30 min, following which two sequences of single-dose administrations in each strip were performed; one to evoke priming relaxations to 5-HT (10 μM), which was followed by one to construct concentration-response curves to 5-HT or a tryptamine analogue. The priming sequence was initiated by precontraction with carbachol (CCh, 0.15 μM), which, after 15 min, was followed by addition of 5-HT (10 μM) to relax the tissue. After the maximum response to 5-HT had been reached, the organ bath solution was replaced twice. Thereafter, a period of 5 min of stabilization was followed by a third replacement of the organ bath solution. A period of 10 min of stabilization was allowed before the priming sequence was repeated (four times). As the relaxation to 5-HT (10 μM) rapidly reached its maximum but also rapidly declined, it was not feasible to construct curves in a cumulative manner. Therefore, a non-cumulative dosing cycle was chosen to construct curves to agonists, as is outlined in the following dosing sequence: Antagonist or vehicle was administered and left to equilibrate for 10 min, followed by addition of carbachol (0.15 μM) to the organ bath to contract the tissue. After 15 min the response to carbachol was stable, and a single dose of a 5-HT receptor agonist was added. After the maximum relaxation to the agonist was obtained, the organ bath solution was replaced twice and left to equilibrate for 5 min. Then, the organ bath solution was replaced for the third time and the dosing sequence was repeated applying the next concentration of a 5-HT receptor agonist (starting at

10 nM, progressing at half-log unit increments). One curve was obtained per strip and one strip served to provide a control curve to 5-HT per specimen of large intestine obtained. Each response to the dose of carbachol (0.15  $\mu$ M) added to contract the tissue was taken as 100% to normalize the agonist-induced relaxation of that specific carbachol-induced contraction.

#### Data analysis and statistics

Agonist parameters (mid-point location  $pEC_{50}$ , maximum relaxation  $\alpha$  and Hill slope  $n_H$ ) and antagonist parameters ( $pK_B$  or  $pA_2$ ) were estimated as described previously (Black *et al.*, 1985). When the treatment did not affect the shape of the curve to 5-HT, any shift was presented as  $\Delta pEC_{50}$ , which was estimated as the absolute value of the average  $pEC_{50, \text{control}}$  – the average  $pEC_{50, \text{treatment}}$ . Results were expressed in terms of mean curve parameters  $\pm$  s.e.mean, and mean original data  $\pm$  s.e.mean, when curve fitting was not possible. Analysis of variance (ANOVA) was performed, followed by a *post hoc* Bonferroni's test for multiple comparisons or a Student's *t*-test in the case of a single treatment. A level of  $P < 0.05$  was considered to indicate a statistical significant difference. The number of experiments carried out is denoted by  $n$ .

#### Compounds

The following compounds were used (with their abbreviations, if any, in italics, and respective suppliers between brackets): (1-butyl-4-piperidinyl)methyl-8-amino-7-chloro-1,4-benzodioxane-5-carboxylate HCl (SB 204070), granisetron HCl, mesulergine HCl, 5-methoxytryptamine (5-MeOT), 2-methyl-5-HT (2-Me-5-HT) (Janssen Research Foundation, Belgium), carbachol (CCh; Merck, Germany), methysergide maleate (Sandoz, Switzerland), tetrodotoxin, 5-hydroxytryptamine creatinine sulphate (5-HT; Serva, Germany), 5-carboxamido-tryptamine maleate (5-CT; Tocris Cookson, U.K.).


The compounds were dissolved in distilled water. Distilled water (1 ml) had no effect on the concentration-response curve. All solutions were prepared freshly on the day of the experiment.

**Results** In the presence of methysergide (1  $\mu$ M; 5-HT<sub>1</sub>, 5-HT<sub>2</sub>, 5-HT<sub>5</sub>, 5-HT<sub>6</sub> and 5-HT<sub>7</sub> receptor antagonist), 5-HT induced a relaxation of carbachol (0.15  $\mu$ M)-induced contractions (Figure 1A) that was sensitive to 5-HT<sub>4</sub> receptor blockade (10 nM SB 204070; Figure 1B). Under 5-HT<sub>4</sub> receptor-blocking conditions in the absence of methysergide, 5-HT still induced a relaxation (Figure 1C). From this point, the relaxation to 5-HT and the tryptamine analogues tested in the current study, were tested in the presence of SB 204070 (10 nM). Concentration-response curves to 5-HT were sigmoidal ( $pEC_{50} 6.3 \pm 0.2$ ; Figure 2). The 5-HT analogues 5-MeOT, 5-CT and 2-Me-5-HT all induced relaxations yielding the following rank order of agonist potency (with concomitant  $pEC_{50}$  values between parentheses): 5-HT ( $6.3 \pm 0.2$ ) = 5-MeOT ( $6.3 \pm 0.2$ ) = 5-CT ( $6.3 \pm 0.2$ ) > 2-Me-5-HT ( $5.3 \pm 0.1$ ) (Figure 2). The curves to the four agonists tested displayed maximum responses that were not significantly different from each other. The curve to 2-Me-5-HT was relatively steep (Hill slope parameter  $1.7 \pm 0.3$ ) as compared to 5-HT ( $0.9 \pm 0.1$ ), 5-MeOT ( $0.8 \pm 0.1$ ) and 5-CT ( $0.8 \pm 0.1$ ).


Mesulergine, at concentrations of 30, 100 and 300 nM, competitively antagonized the 5-HT-induced relaxation (Figure 3), yielding a Schild slope of  $0.9 \pm 0.2$  (not significantly different from unity) and a  $pK_B$  estimate of  $8.3 \pm 0.1$ .

Mesulergine (100 nM) also significantly inhibited the 5-CT-induced relaxation (Student's *t*-test,  $P < 0.05$ ), but the maximum response to 5-CT in the presence of mesulergine was not obtained. Therefore, curve fitting could not be performed on these data (Figure 2). By inspection, the antagonism appeared insurmountable. Furthermore, the increased relaxation at the highest concentration of 5-CT administered (30  $\mu$ M) may be indicative of a second phase. Methysergide (100 nM) shifted the curve to 5-HT rightward in a parallel manner ( $pA_2 7.6$ , Figure 4).

The curve to 5-HT was affected neither by tetrodotoxin (0.3  $\mu$ M;  $\Delta pEC_{50} 0.04$ ;  $n = 6$ ; data not shown) nor by a 10 fold increase of the concentration of SB 204070 (to 100 nM;  $\Delta pEC_{50} 0.04$ ;  $n = 6$ ; data not shown). The selective 5-HT<sub>3</sub> receptor




**Figure 1** Chart recorder tracings of 5-HT (10  $\mu$ M)-induced effects on CCh (0.15  $\mu$ M)-contracted circular muscle strips of human sigmoid colon. 5-HT induces a relaxation in the presence of methysergide (1  $\mu$ M; A) that was sensitive to 5-HT<sub>4</sub> receptor blockade by SB 204070 (10 nM; B). When SB 204070 (10 nM) was used only, 5-HT still induced a relaxation of the muscle strips (C).




**Figure 2** Concentration-relaxation curves to 5-MeOT, 5-CT, 5-HT and 2-Me-5-HT in the human colonic circular muscle preparation in the presence of SB 204070 (10 nM). The curves shown superimposed on the vertically averaged experimental data points represent simulations using the Hill equation and the parameters for upper asymptote (shown with vertical error bars) and midpoint location (shown with horizontal error bars) and the Hill slope that were obtained from the iterative fitting procedure. The data points of the curve to 5-CT obtained in the presence of mesulergine (MES) could not be fitted to the Hill equation and are presented as vertically averaged experimental data points  $\pm$  s.e.mean.

antagonist granisetron ( $0.3 \mu\text{M}$ ;  $n=6$ ) failed to affect the curve to 5-HT ( $\Delta\text{EC}_{50} 0.02$ ), thus ruling out involvement of 5-HT<sub>3</sub> receptors (data not shown).

**Discussion** In the current study, it was demonstrated that in addition to 5-HT<sub>4</sub> receptors, 5-HT<sub>7</sub> receptors also mediate relaxation of human colon circular smooth muscle. First, it was confirmed that 5-HT<sub>4</sub> receptors mediate relaxation (Figure



**Figure 3** Competitive antagonism by mesulergine (MES) of the 5-HT-induced relaxation of human colonic circular muscle in the presence of SB 204070 (10 nM). The curves shown superimposed on the vertically averaged experimental data points represent simulations using the Hill equation and the parameters for upper asymptote (shown with vertical error bars) and midpoint location (shown with horizontal error bars) and the Hill slope that were obtained from the iterative fitting procedure.



**Figure 4** Antagonism by methysergide of the 5-HT-induced relaxation of human colonic circular muscle obtained in the presence of SB 204070 (10 nM). The curves shown superimposed on the vertically averaged experimental data points represent simulations using the Hill equation and the parameters for upper asymptote (shown with vertical error bars) and midpoint location (shown with horizontal error bars) and the Hill slope that were obtained from the iterative fitting procedure.

1) as SB 204070 (10 nM) blocked the relaxation to 5-HT in the presence of methysergide (1  $\mu\text{M}$ ). After selective blockade of 5-HT<sub>4</sub> receptors in the absence of methysergide, 5-HT still induced a relaxation. The hypothesis that 5-HT<sub>4</sub> receptors mediated this 5-HT-induced relaxation as a result of insufficient 5-HT<sub>4</sub> receptor blockade by SB 204070 (10 nM), was ruled out by the failure of a 10 fold higher concentration of SB 204070 (100 nM) to further affect the 5-HT-induced relaxation. The inability of tetrodotoxin to affect the 5-HT-induced relaxation suggests that the 5-HT receptor is located on the smooth muscle. Receptors on the smooth muscle that mediate relaxation are most likely coupled to adenylate cyclase activation. Of the known 5-HT receptors, 5-HT<sub>4</sub>, 5-HT<sub>6</sub> and 5-HT<sub>7</sub> receptors are positively coupled to adenylate cyclase (Hoyer *et al.*, 1994). As SB 204070 (10 nM) adequately blocked 5-HT<sub>4</sub> receptors, 5-HT<sub>6</sub> and 5-HT<sub>7</sub> receptors would be the most likely candidates to mediate the 5-HT-induced relaxation. Involvement of 5-HT<sub>6</sub> receptors, however, was ruled out by the antagonism induced by the potent 5-HT<sub>7</sub> antagonist mesulergine ( $\text{pK}_B$  8.3), which possesses only micromolar affinity for 5-HT<sub>6</sub> receptors (Gommeren *et al.*, 1998). Mesulergine also binds with nanomolar affinity to 5-HT<sub>2</sub> receptors, but 5-HT<sub>2</sub> receptors are coupled to IP<sub>3</sub> hydrolysis, and, if located on smooth muscle, would be expected to mediate contraction. For the same reason, involvement of 5-HT<sub>1</sub> receptors as well as 5-HT<sub>5</sub> receptors is highly unlikely, as these receptors are negatively coupled to adenylate cyclase, and, if located on the smooth muscle, would not be expected to be associated with relaxation (Hoyer *et al.*, 1994).

The  $\text{pK}_B$  estimate for mesulergine (8.3) against 5-HT agrees well with the affinity estimates obtained in the 5-HT<sub>7</sub> receptor bioassays of the guinea-pig ileum (7.8: Carter *et al.*, 1995), rat jejunum (8.1: McLean & Coupar, 1996), and at the cloned human 5-HT<sub>7</sub> receptor expressed in CHO cell lines (8.2: Gommeren *et al.*, 1998). It cannot be excluded that the apparent non-monophasic shape of the curve to 5-CT in the presence of mesulergine reflects either insurmountable antagonism by mesulergine or a second relaxant property of 5-CT, in addition to 5-HT<sub>7</sub> receptor agonism. Nevertheless, mesulergine demonstrates that the 5-CT-induced relaxation is primarily 5-HT<sub>7</sub> receptor-mediated. Methysergide is also an antagonist of 5-HT<sub>7</sub> receptors ( $\text{pA}_2$  7.6: Carter *et al.*, 1995) and the affinity obtained in the current study ( $\text{pA}_2$  7.6) points to antagonism of 5-HT<sub>7</sub> receptors. The relaxation to 5-HT, therefore, is likely to be mediated by 5-HT<sub>7</sub> receptors.

Accordingly, the similar potency of 5-CT, 5-HT and 5-MeOT is in good agreement with involvement of 5-HT<sub>7</sub> receptors (Terron, 1998). However, 2-Me-5-HT was markedly less potent, and gave a Hill slope that was twice as steep as the Hill slope of the more potent, equi-efficacious agonists 5-HT, 5-MeOT and 5-CT. The operational model of agonism (Black & Leff, 1983) predicts that when an agonist displays a lower potency accompanied by a markedly steeper Hill slope than other agonists, but the same maximum response, then the agonist does not elicit that response *via* the same receptor or mechanism. Thus, 2-Me-5-HT might not have activated 5-HT<sub>7</sub> receptors in the current study, which is not unlikely, as Zondag *et al.* (1994) reported that 2-Me-5-HT relaxed guinea-pig colonic tissue through activation of  $\alpha_1$ -adrenoceptors.

5-HT<sub>7</sub> receptors have been cloned from a number of species including man (for review: see Terron, 1998). Functional correlates were found in several animal species (guinea-pig: Carter *et al.*, 1995; cat: Villalon *et al.*, 1997; monkey: Leung *et al.*, 1996). The first indication that gastrointestinal 5-HT<sub>7</sub> receptors might be present in humans was found by Bard *et al.* (1993), who demonstrated abundant expression of 5-HT<sub>7</sub>

receptor mRNA in human brain, colon, ileum and stomach in comparison with low expression in the spleen, liver and kidney. The present study indicates that in the colon, the 5-HT<sub>7</sub> receptor mRNA is translated into functional 5-HT<sub>7</sub> receptors. Additionally, this study might explain why previously, selective 5-HT<sub>4</sub> receptor antagonists (SB 207710 and GR 113808) were found not to behave competitively, as judged from the Schild slopes which were significantly less than unity (McLean & Coupar, 1995; Tam *et al.*, 1995). The presence of methysergide and ondansetron (both 10  $\mu$ M) changed the Schild slope of the selective 5-HT<sub>4</sub> receptor antagonist SB 207710 from 0.5 to 1 (McLean & Coupar, 1995). Thus, methysergide presumably antagonized the 5-HT<sub>7</sub> receptor component (as it did in the present study; Figure 4), exposing a 5-HT-induced relaxation that was entirely mediated by 5-HT<sub>4</sub> receptors.

## References

BARD, J.A., ZGOMBICK, J., ADHAM, N., VAYSSE, P., BRANCHEK, T.A. & WEINSHANK, R.L. (1993). Cloning of a novel human serotonin receptor (5-HT<sub>7</sub>) positively linked to adenylate cyclase. *J. Biol. Chem.*, **268**, 23422–23426.

BLACK, J.W. & LEFF, P. (1983). Operational models of pharmacological agonism. *Proc. R. Soc. (Lond. B.)*, **220**, 141–162.

BLACK, J.W., LEFF, P. & SHANKLEY, N.P. (1985). Further analysis of anomalous pK<sub>B</sub> values for histamine H<sub>2</sub>-receptor antagonists on the mouse isolated stomach assay. *Br. J. Pharmacol.*, **86**, 581–587.

CARTER, D., CHAMPNEY, M., HWANG, B. & EGLEN, R.M. (1995). Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum. *Eur. J. Pharmacol.*, **280**, 243–250.

GOMMEREN, W., RENDERS J., VAN GOMPEL P., LESAGE A., LEYSEN, J. & JURZAK, M. (1998). Extensive pharmacological study of the G protein-coupled fraction of human 5-HT receptors using agonist radioligand binding. *Naunyn-Schmiedebergs' Arch. Pharmacol.*, **358**, P8.42.

HOYER, D., CLARKE, D.E., FOZARD, J.R., HARTIG, P.R., MARTIN, G.R., MYLECHARANE, E.J., SAXENA, P.R. & HUMPHREY, P.P.A. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). *Pharmacol. Rev.*, **46**, 157–203.

LEUNG, E., WALSH, L.K., PULIDO-RIOS, M.T. & EGLEN, R.M. (1996). Characterization of putative 5-HT<sub>7</sub> receptors mediating direct relaxation in Cynomolgus monkey isolated jugular vein. *Br. J. Pharmacol.*, **117**, 926–930.

MCLEAN, P.G. & COUPAR, I.M. (1995). 5-HT<sub>4</sub> receptor antagonist affinities of SB207710, SB205008, and SB203186 in the human colon, rat oesophagus, and guinea-pig ileum peristaltic reflex. *Naunyn-Schmiedebergs' Arch. Pharmacol.*, **352**, 132–140.

MCLEAN, P.G., COUPAR, I.M. & MOLENAAR, P. (1995). A comparative study of functional 5-HT<sub>4</sub> receptors in human colon, rat oesophagus and rat ileum. *Br. J. Pharmacol.*, **115**, 47–56.

MCLEAN, P.G. & COUPAR, I.M. (1996). Characterisation of a postjunctional 5-HT<sub>7</sub>-like and a prejunctional 5-HT<sub>3</sub> receptor mediating contraction of rat isolated jejunum. *Eur. J. Pharmacol.*, **312**, 215–225.

TAM, F.S., HILLIER, K., BUNCE, K.T. & GROSSMAN, C. (1995). Differences in response to 5-HT<sub>4</sub> receptor agonists and antagonists of the 5-HT<sub>4</sub>-like receptor in human colon circular smooth muscle. *Br. J. Pharmacol.*, **115**, 172–176.

TERRON, J.A. (1998). The 5-HT<sub>7</sub> receptor: A target for novel therapeutic avenues? *IDRUGS*, **1**, 302–310.

VILLALON, C.M., HEILIGERS, J.P., CENTURION, D., DE VRIES, P. & SAXENA, P.R. (1997). Characterization of putative 5-HT<sub>7</sub> receptors mediating tachycardia in the cat. *Br. J. Pharmacol.*, **121**, 1187–1195.

ZONDAG, C.H.J., GROSSMAN, C.J. & BUNCE, K.T. (1994). Investigation of the receptor mechanism mediating the relaxation response to 2-methyl-5-hydroxytryptamine in guinea-pig ascending colon. *Br. J. Pharmacol.*, **112** (suppl): 177P.

In conclusion, when 5-HT<sub>4</sub> receptors are blocked, the relaxation of human colon by 5-HT is mediated by smooth muscle 5-HT<sub>7</sub> receptors. The presence of 5-HT<sub>7</sub> receptors might explain the previously reported deviation from simple competitive behaviour of selective 5-HT<sub>4</sub> receptor antagonists when their effects against 5-HT-induced relaxation were assessed. This report provides the first account of functional human (peripheral) 5-HT<sub>7</sub> receptors.

The authors wish to thank Dr Cheyns from 'Algemeen Ziekenhuis St. Jozef', Turnhout, Belgium, for providing human colonic specimens.

(Received May 7, 1999)

Revised June 7, 1999

Accepted June 16, 1999